Noriega Esquives Blanca S, Manoharan Aysswarya, Penedo Frank J, Dee Edward C, Mahal Brandon A, Punnen Sanoj, Rodriguez-Saltzman Xeniamaria, Perreira Krista M, Parada Humberto, Argos Maria, Hougen Helen Y
Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, Florida, USA.
University of Miami Miller School of Medicine, Miami, Florida, USA.
Cancer. 2025 Aug 15;131(16):e70029. doi: 10.1002/cncr.70029.
Disparities exist in prostate cancer (PCa) treatment and outcomes among Hispanic/Latino men. This study aimed to determine the prevalence and predictors of PCa screening among Hispanic men of diverse backgrounds.
Among men aged 40+ years (n = 3484) who participated in the Hispanic Community Health Study/Study of Latinos, the prevalence of prostate-specific antigen (PSA) screening and the odds of ever having a PSA test, given sociodemographic, psychosocial, medical, and health care access factors, were estimated.
PSA screening increased with age (40-54 years, 20%; 55-69 years, 46%; 70+ years, 56%). Compared to White Hispanic men, Black Hispanic men had the lowest odds of screening (odds ratio [OR], 0.24 for age 40-54 years; OR, 0.31 for age 55-69 years). Compared to men of Mexican descent, men of Cuban descent had the lowest odds of screening (OR, 0.41 for age 55-69 years; OR, 0.32 for age 70+ years). Among those aged 40-54 years, younger age, lower family cohesion, lower chronic stress, and not having a designated primary care site predicted a lack of PSA screening. For men aged 55-69 years, lower body mass index, low social support, no primary care provider (PCP), and remote routine checkups predicted a lack of PSA screening. For men aged 70+ years, the odds of screening decreased with low educational attainment and not having a PCP.
Black Hispanics are significantly less likely to receive PSA screening compared with non-Black Hispanic counterparts. Cuban heritage and poor primary or routine health care access also predicted lower screening. These findings underscore the screening heterogeneity in this diverse community, and highlight areas of targeted intervention to reduce disparities.
西班牙裔/拉丁裔男性在前列腺癌（PCa）治疗和预后方面存在差异。本研究旨在确定不同背景的西班牙裔男性中前列腺癌筛查的患病率及预测因素。
在参与西班牙裔社区健康研究/拉丁裔研究的40岁及以上男性（n = 3484）中，估计前列腺特异性抗原（PSA）筛查的患病率以及在考虑社会人口学、心理社会、医疗和医疗保健可及性因素的情况下进行PSA检测的几率。
PSA筛查率随年龄增长而增加（40 - 54岁为20%；55 - 69岁为46%；70岁及以上为56%）。与西班牙裔白人男性相比，西班牙裔黑人男性进行筛查的几率最低（40 - 54岁时比值比[OR]为0.24；55 - 69岁时OR为0.31）。与墨西哥裔男性相比，古巴裔男性进行筛查的几率最低（55 - 69岁时OR为0.41；70岁及以上时OR为0.32）。在40 - 54岁的人群中，年龄较小、家庭凝聚力较低、慢性压力较小以及没有指定的初级保健机构预示着缺乏PSA筛查。对于55 - 69岁的男性，较低的体重指数、低社会支持、没有初级保健提供者（PCP）以及常规检查地点较远预示着缺乏PSA筛查。对于70岁及以上的男性，筛查几率随着教育程度低和没有PCP而降低。
与非黑人西班牙裔男性相比，西班牙裔黑人接受PSA筛查的可能性显著更低。古巴裔背景以及初级或常规医疗保健可及性差也预示着筛查率较低。这些发现强调了这个多元化社区中筛查的异质性，并突出了针对性干预以减少差异的领域。
